Kala Pharmaceuticals Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Business Wirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBusiness Wire2017-05-01 08:15:232017-05-01 14:58:11Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery